Who Paid My Doc
A Phase II, Randomised, Observer-Blind, Placebo Controlled Multi-Count
Research payments
$987,604
Through program year 2022, $987,604 in research payments was reported against A Phase II, Randomised, Observer-Blind, Placebo Controlled Multi-Count, across 176 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $18,086 | 8 |
| 2021 | Research | $2,032 | 2 |
| 2020 | Research | $967,486 | 166 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Cynthia Robbins Fort Worth, TX Named on 30 payments
- Robert Jeanfreau Metairie, LA Named on 22 payments
- Paul Matherne Gulfport, MS Named on 22 payments
- Charles Plimpton Phoenix, AZ Named on 18 payments
- Albert Nassir Huntington Park, CA Named on 16 payments
- Gary Gregerson Nampa, ID Named on 15 payments
- Peyman Banooni Maywood, CA Named on 13 payments
- Marquita Anderson Beaumont, TX Named on 10 payments
- Stuart Weprin Englewood, OH Named on 10 payments
- Dhruv Agneshwar Binghamton, NY Named on 7 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.